Manipal Health Enterprises (NSE:MANIPALHOS) 3-Year EBITDA Growth Rate: 0.00% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:MANIPALHOS Manipal Health Enterprises Ltd NSE:MANIPALHOS
13 GF Score
Price ₹771.65
! 1 Warning Sign
View Full Analysis

What is Manipal Health Enterprises 3-Year EBITDA Growth Rate?

Manipal Health Enterprises NSE:MANIPALHOS -3.30% 13 3-Year EBITDA Growth Rate is 0.00% as of Mar. 2026. GuruFocus rates NSE:MANIPALHOS with a GF Score™ of 13/100. The stock has 1 warning sign investors should review. Among 526 Healthcare Providers & Services companies, Manipal Health Enterprises ranks worse than 190113.88% on this metric.

Manipal Health Enterprises's EBITDA per Share for the six months ended in Mar. 2026 was ₹21.55.

During the past 12 months, Manipal Health Enterprises's average EBITDA Per Share Growth Rate was 15.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Manipal Health Enterprises  (NSE:MANIPALHOS) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Manipal Health Enterprises 3-Year EBITDA Growth Rate Related Terms

NSE:MANIPALHOS vs HCA, THC, EHC: 3-Year EBITDA Growth Rate Comparison

For the Medical Care Facilities subindustry, Manipal Health Enterprises's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Manipal Health Enterprises 3-Year EBITDA Growth Rate vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Manipal Health Enterprises's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Manipal Health Enterprises's 3-Year EBITDA Growth Rate falls into.


NSE:MANIPALHOS
13GF Score
Manipal Health Enterprises Ltd NSE:MANIPALHOS
3-Year EBITDA Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Manipal Health Enterprises 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 3-Year EBITDA Growth Rate of 0.00% mean?
Manipal Health Enterprises (NSE:MANIPALHOS) has a 3-Year EBITDA Growth Rate of 0.00% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Manipal Health Enterprises and its competitors. According to the industry distribution chart, Manipal Health Enterprises ranks #999999 out of 526 companies in the Healthcare Providers & Services industry.
Is Manipal Health Enterprises' 3-Year EBITDA Growth Rate too high?
Manipal Health Enterprises' current 3-Year EBITDA Growth Rate is 0.00%. Based on the distribution chart, Manipal Health Enterprises ranks #999999 out of 526 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Manipal Health Enterprises has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Manipal Health Enterprises' 3-Year EBITDA Growth Rate compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Manipal Health Enterprises ranks #999999 out of 526 companies for 3-Year EBITDA Growth Rate. This places Manipal Health Enterprises in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 9.90. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Healthcare Providers & Services company?
The median 3-Year EBITDA Growth Rate among Healthcare Providers & Services companies is 9.90, based on 526 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Manipal Health Enterprises and its competitors. For the Healthcare Providers & Services industry, the median 3-Year EBITDA Growth Rate is 9.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Manipal Health Enterprises's current 3-Year EBITDA Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Manipal Health Enterprises stock overvalued right now?
Manipal Health Enterprises (NSE:MANIPALHOS) has a current 3-Year EBITDA Growth Rate of 0.00%. The current 3-Year EBITDA Growth Rate is 0.00%. Manipal Health Enterprises' overall GF Score™ is 13/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Manipal Health Enterprises (NSE:MANIPALHOS), the current 3-Year EBITDA Growth Rate is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Manipal Health Enterprises Business Description

Other Exchanges 544847:India
Address HAL Airport Road, Rustom Bagh road, The Annexe, no. 98/2, Bengaluru, KA, IND, 560 017
Manipal Health Enterprises Ltd is engaged in the business of running/managing hospitals and providing healthcare services. The company operates through various Hospitals/clinics providing Healthcare services and diagnostic centres in India. It offers clinical services across several specialties, with a focus on tertiary and quaternary care, particularly in cardiac sciences, oncology, neurosciences, gastro sciences, orthopedics, and renal sciences. It has a single business segment, namely engaged in the business of healthcare services. The company generates revenue by providing inpatient care at its hospitals.
13GF Score

Get the complete analysis for NSE:MANIPALHOS

3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹771.65
Price